

Walter P. Scheffe Continuing Pharmacy Education Series

November 8-9, 2025

The University of Oklahoma Health Campus
College of Pharmacy | Room 103
1110 N. Stonewall Ave.
Oklahoma City, OK 73117

Produced and Hosted By



The University of Oklahoma College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Contact Information

For questions, concerns, grievances or accommodations, please contact Cassidy Roberts, OU College of Pharmacy CPE Administrator, at Cassidy-Roberts@ou.edu or (405) 271-6194.

Registration

Pre-registration is suggested to allow OUCOP to provide the appropriate faculty and materials necessary to meet the program objectives. Pre-registration is \$150/day and will be accepted until 11/7/25. On-site registration is \$165/day. This includes all activity materials, continental breakfast, lunch and refreshments. Participants will be emailed a link to download/print program documents four days in advance. Wi-Fi will be available on-site for those who would like to follow along on their device. We reserve the right to limit registrations or cancel courses. There are no refunds unless the seminar is canceled.

Name	Practice Setting
NABP e-Profile ID	Birthday (MMDD)
Email	Day(s) Attending (Sat, Sun, Both)
Workplace/Employer	Dietary Restrictions

_____ I will download/print my own materials.

_____ I would like my materials printed for me.

Payment Method

_____ Credit Card | Visit our secure website at:
<https://pharmacy.ouhsc.edu/marketplace> → Alumni/Continuing Education

_____ Check (include check #) | Mail with registration form to: OU
College of Pharmacy, P.O. Box 26901, CPB 104D, OKC, OK 73126

Agenda

Sat, 11/8 | 8 contact hours (0.8 CEUs)

- 7:30-7:55am **Registration & Breakfast**
- 7:55-8:00am **Introduction**
- 8:00-9:30am **Staying Compliant with the Oklahoma State Board of Pharmacy* (K)**
ACPE# 0053-0000-25-027-L03-P 1.5 contact hours (.15 CEUs)
Marjan Fardadfar, Pharm.D., D.Ph., BCGP
- 9:30-10:30am **Updates on Heart Failure with Preserved Ejection Fraction* (A)**
ACPE# 0053-0000-25-028-L01-P 1 contact hour (0.1 CEU)
Moriah Willis, Pharm.D.
- 10:30-10:45am **Break**
- 10:45-12:15pm **Oncology (Title TBA)* (K)**
ACPE# 0053-0000-25-029-L01-P 1.5 contact hours (.15 CEUs)
Ashtin Taylor, Pharm.D.
- 12:15-12:45pm **Lunch Break**
- 12:45-2:45pm **Dispensing Care: How OPHP Supports Mental Health in Pharmacy Professionals* (K)**
ACPE# 0053-0000-25-030-L01-P 2 contact hours (0.2 CEUs)
Tammy Lambert, Pharm.D., Ph.D.
- 2:45-3:00pm **Break**
- 3:00-5:00pm **Tackling Toxic Trends: Poison Center Strategies for Managing Opioid, Stimulant, Marijuana and Newer Drugs of Abuse Exposures* (A)**
ACPE# 0053-0000-25-031-L01-P 2 contact hours (0.2 CEUs)
Kristie Edelen, Pharm.D., DABAT
- 5:00-5:05pm **Closing Remarks**

*Denotes sessions of continuing education credit
(K)=Knowledge-based (A)=Application-based

Sun, 11/9 | 7 contact hours (0.7 CEUs)

- 7:30-7:55am **Registration & Breakfast**
- 7:55-8:00am **Introduction**
- 8:00-9:30am **Beyond the Hospital Walls: Antimicrobial Stewardship in the Outpatient Pharmacy Setting* (K)**
ACPE# 0053-0000-25-032-L01-P 1.5 contact hours (.15 CEUs)
Madison Riojas, Pharm.D., BCIDP
- 9:30-9:45am **Break**
- 9:45-10:45am **Tending our Public Health Garden: Keeping out of the Political Weeds and Finding the Evidence-based Fruit* (A)**
ACPE# 0053-0000-25-033-L04-P 1 contact hour (0.1 CEU)
Jacki Travers, Pharm.D.
- 10:45-11:45am **Optimizing Glycemic Control: An Overview of Diabetes Pharmacotherapy* (A)**
ACPE# 0053-0000-25-034-L01-P 1 contact hour (0.1 CEU)
Hayley Sewell, Pharm.D., BCACP
- 11:45-12:15pm **Lunch Break**
- 12:15-1:15pm **From Echinacea to Evidence: Herbs and Supplements for Cold and Flu Season* (A)**
ACPE# 0053-0000-25-035-L01-P 1 contact hour (0.1 CEU)
Paul Boylan, Pharm.D., BCPS
- 1:15-2:15pm **Immunization Update 2025: What Pharmacists Need to Know* (A)**
ACPE# 0053-0000-25-036-L06-P 1 contact hour (0.1 CEU)
Susan Conway, Pharm.D., FASHP, BCACP
- 2:15-2:30pm **Break**
- 2:30-4:00pm **Alzheimer's Therapy: From Symptom Management to Disease Modifying Options* (K)**
ACPE# 0053-0000-25-037-L01-P 1.5 contact hours (.15 CEUs)
Amanda Sharpe, Ph.D.
- 4:00-4:05pm **Closing Remarks**

CPE Credit

This seminar offers a total of 15 contact hours (1.5 CEUs) of ACPE-accredited continuing pharmacy education (CPE) credit accepted by all U.S. boards of pharmacy. Credit is earned based on attendance and participation in individually accredited activities. Partial credit will not be awarded. Those who arrive over 10 minutes late or leave early will not be granted credit. For successful attendance verification and activity completion, each participant must sign in on the morning and afternoon sign-in sheets, provide NABP e-Profile ID and birthday (MMDD), participate in the learning assessments, return nametag at the end of the final session attended, and complete the online program evaluation. The University of Oklahoma College of Pharmacy (OUCOP), as an ACPE-accredited provider, is required to report credit online through CPE Monitor. Credit will be uploaded within four weeks of the seminar and participants will be notified via email. The initial release date is 11/8/25 (Sat) and 11/9/25 (Sun).

Continuing education activities are structured to meet knowledge- and/or application-based education needs. A knowledge-based activity is for participants to acquire factual knowledge. An application-based activity is for participants to apply the information learned in the allotted timeframe. Information in all CPE activities is based on evidence as accepted in the literature by the health care professions.

Policies & Procedures

The University of Oklahoma (OU) is an equal opportunity institution. Accommodations on the basis of disability are available by contacting Cassidy-Roberts@ou.edu. We are committed to protecting the privacy of our learners. Your personal information will not be shared with anyone outside OUCOP unless you consented to your name and practice site being shared with vendor representatives, if applicable. In that case, no contact details or any other information will be given out. Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of OU/OUCOP or is licensed or has been granted permission for use by the copyright owner. No materials may be reproduced or transmitted without written permission. All rights reserved. To access the entirety of these policies, visit [Terms of Use](#) and [Policies and Procedures](#).

Target Audience & Learning Objectives

This continuing pharmacy education program is intended for pharmacists in any practice setting. At the completion of this activity, the participant will be able to:

ACPE # 0053-0000-25-027-L03-P (K)

Recall recent pharmacy law updates in Oklahoma
Recognize common violations cited in annual board inspections
List best practices for integrating legal requirements into pharmacy workflows

ACPE # 0053-0000-25-028-L01-P (A)

Differentiate heart failure with preserved ejection fraction (HFpEF) from heart failure with reduced ejection fraction (HFrEF)
Analyze findings from past HFpEF clinical trials to determine their impact on current treatment approaches and clinical guidelines
Examine recent HFpEF clinical trials and their potential influence on future therapeutic strategies

ACPE # 0053-0000-25-029-L01-P (K)

Learning objectives TBA

ACPE # 0053-0000-25-030-L01-P (K)

Describe the characteristics of occupational stress and burnout
Explain how occupational stress impacts pharmacy staff health and performance
Identify the differences between temporary stress responses and mental health disorders
List the clinical features and symptoms of generalized anxiety disorder, major depressive disorder, substance use disorder, and episodes of psychosis
Define professional enabling
State how Oklahoma Pharmacists Helping Pharmacists can help pharmacy staff who are struggling with a mental health disorder

ACPE # 0053-0000-25-031-L01-P (A)

Examine real-time poison center surveillance data to track emerging trends in substance-related exposures
Describe how poison centers support cases involving opioids, stimulants, marijuana and newer drugs of abuse
Differentiate the clinical presentations and key features of opioid, stimulant, marijuana and newer drugs of abuse exposures
Employ evidence-based protocols to manage suspected overdoses or toxic exposures

ACPE # 0053-0000-25-032-L01-P (K)

Recognize regional trends in antimicrobial susceptibility in Oklahoma
Identify barriers to antimicrobial stewardship in the outpatient

pharmacy setting
Outline strategies pharmacists can use to improve antimicrobial use
Describe the importance of interprofessional collaboration in antimicrobial stewardship efforts

ACPE # 0053-0000-25-033-L04-P (A)

Compare published studies by their level of evidence
Apply the PICO(T) methodology to a given topic
Examine the reliability and validity of published studies
Classify existing studies using their impact factor

ACPE # 0053-0000-25-034-L01-P (A)

Examine treatment goals and adjustments for populations with special considerations
Identify diabetes medications with ASCVD, HF, and/or CKD benefits
Choose appropriate treatment plans for people with diabetes using the 2025 ADA Standards of Care

ACPE # 0053-0000-25-035-L01-P (A)

Use three databases that provide evidence-based information on herbals and supplements
Describe the efficacy and safety of common herbals and supplements used during respiratory virus season
Choose optimal herbals and supplements to treat a patient with a respiratory virus

ACPE # 0053-0000-25-036-L06-P (A)

Describe newly approved vaccines and updated recommendations for existing vaccines
Employ current authoritative guidelines and immunization schedules for appropriate vaccine selection and scheduling
Examine the rationale and patient care implications of recent immunization changes

ACPE # 0053-0000-25-037-L01-P (K)

Recall the pathogenesis of Alzheimer's disease and how it varies from healthy aging
Summarize advances in diagnosis and monitoring of disease progression for Alzheimer's disease
Identify currently approved therapeutic treatment options for Alzheimer's disease
Review recent clinical data on emerging targets for Alzheimer's disease therapy
Explain the risks, benefits, and patient selection considerations for monoclonal antibody treatments

Faculty

Paul Boylan, Pharm.D., BCPS

Associate Professor | OU College of Pharmacy, OKC

Susan Conway, Pharm.D., FASHP, BCACP

Professor and Director of Experiential Education
OU College of Pharmacy, OKC

Kristie Edelen, Pharm.D., DABAT

Managing Director | Oklahoma Poison Center, OKC

Marjan Fardadford, Pharm.D., D.Ph., BCGP

Compliance Officer
Oklahoma State Board of Pharmacy, OKC

Tammy Lambert, Pharm.D., Ph.D.

Clinical Assistant Professor
OU College of Pharmacy, OKC

Madison Riojas, Pharm.D., BCIDP

Antimicrobial Stewardship Pharmacist
Oklahoma State Department of Health, OKC

Hayley Sewell, Pharm.D., BCACP

Assistant Professor | OU College of Pharmacy, OKC

Amanda Sharpe, Ph.D.

Associate Professor | OU College of Pharmacy, OKC

Ashtin Taylor, Pharm.D.

Clinical Oncology Pharmacist
OU Health Stephenson Cancer Center, OKC

Jacki Travers, Pharm.D.

Clinical Pharmacist
Pharmacy Management Consultants, OKC

Moriah Willis, Pharm.D.

PGY2 Resident | OU College of Pharmacy, OKC

The University of Oklahoma College of Pharmacy has reviewed all faculty and planner disclosures and mitigated any relevant financial relationships with ineligible companies that exist. Details will be provided to registrants before the activity. No commercial support was received for this program.